Literature DB >> 24447516

Ca(v)3.2 calcium channels: the key protagonist in the supraspinal effect of paracetamol.

Nicolas Kerckhove1, Christophe Mallet, Amaury François, Mathieu Boudes, Jean Chemin, Thomas Voets, Emmanuel Bourinet, Abdelkrim Alloui, Alain Eschalier.   

Abstract

To exert its analgesic action, paracetamol requires complex metabolism to produce a brain-specific lipoamino acid compound, AM404, which targets central transient receptor potential vanilloid receptors (TRPV1). Lipoamino acids are also known to induce analgesia through T-type calcium-channel inhibition (Ca(v)3.2). In this study we show that the antinociceptive effect of paracetamol in mice is lost when supraspinal Ca(v)3.2 channels are inhibited. Therefore, we hypothesized a relationship between supraspinal Ca(v)3.2 and TRPV1, via AM404, which mediates the analgesic effect of paracetamol. AM404 is able to activate TRPV1 and weakly inhibits Ca(v)3.2. Interestingly, activation of TRPV1 induces a strong inhibition of Ca(v)3.2 current. Supporting this, intracerebroventricular administration of AM404 or capsaicin produces antinociception that is lost in Ca(v)3.2(-/-) mice. Our study, for the first time, (1) provides a molecular mechanism for the supraspinal antinociceptive effect of paracetamol; (2) identifies the relationship between TRPV1 and the Ca(v)3.2 channel; and (3) suggests supraspinal Ca(v)3.2 inhibition as a potential pharmacological strategy to alleviate pain.
Copyright © 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analgesia; Ca(v)3.2 channel; Paracetamol; TRPV1

Mesh:

Substances:

Year:  2014        PMID: 24447516     DOI: 10.1016/j.pain.2014.01.015

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  20 in total

1.  Analgesic transient receptor potential vanilloid-1-active compounds inhibit native and recombinant T-type calcium channels.

Authors:  Jeffrey R McArthur; Rocio K Finol-Urdaneta; David J Adams
Journal:  Br J Pharmacol       Date:  2019-05-16       Impact factor: 8.739

Review 2.  T-type channel-mediated neurotransmitter release.

Authors:  Emilio Carbone; Chiara Calorio; David H F Vandael
Journal:  Pflugers Arch       Date:  2014-03-06       Impact factor: 3.657

Review 3.  The Contribution of Serotonergic Receptors and Nitric Oxide Systems in the Analgesic Effect of Acetaminophen: An Overview of the Last Decade.

Authors:  Yeşim Hamurtekin; Ammar Nouilati; Cansu Demirbatir; Emre Hamurtekin
Journal:  Turk J Pharm Sci       Date:  2020-02-19

4.  Paracetamol is a centrally acting analgesic using mechanisms located in the periaqueductal grey.

Authors:  David André Barrière; Fawzi Boumezbeur; Romain Dalmann; Roberto Cadeddu; Damien Richard; Jérémy Pinguet; Laurence Daulhac; Philippe Sarret; Kevin Whittingstall; Matthieu Keller; Sébastien Mériaux; Alain Eschalier; Christophe Mallet
Journal:  Br J Pharmacol       Date:  2020-01-22       Impact factor: 8.739

Review 5.  Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action.

Authors:  Samir S Ayoub
Journal:  Temperature (Austin)       Date:  2021-03-16

6.  Painful diabetic neuropathy leads to functional CaV3.2 expression and spontaneous activity in skin nociceptors of mice.

Authors:  Tal Hoffmann; Katrin Kistner; Sonja L J Joksimovic; Slobodan M Todorovic; Peter W Reeh; Susanne K Sauer
Journal:  Exp Neurol       Date:  2021-08-25       Impact factor: 5.330

Review 7.  T-type calcium channels in chronic pain: mouse models and specific blockers.

Authors:  Amaury François; Sophie Laffray; Anne Pizzoccaro; Alain Eschalier; Emmanuel Bourinet
Journal:  Pflugers Arch       Date:  2014-03-04       Impact factor: 3.657

8.  Paracetamol sharpens reflection and spatial memory: a double-blind randomized controlled study in healthy volunteers.

Authors:  Gisèle Pickering; Nicolas Macian; Claude Dubray; Bruno Pereira
Journal:  Drug Des Devel Ther       Date:  2016-12-05       Impact factor: 4.162

9.  Assessment of the effectiveness and safety of Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain: EDONOT-protocol of a randomised, parallel, controlled, double-blinded and multicentre clinical trial.

Authors:  Nicolas Kerckhove; Christophe Mallet; Bruno Pereira; Chouki Chenaf; Christian Duale; Claude Dubray; Alain Eschalier
Journal:  BMJ Open       Date:  2016-12-16       Impact factor: 2.692

10.  The brain signature of paracetamol in healthy volunteers: a double-blind randomized trial.

Authors:  Gisèle Pickering; Adrian Kastler; Nicolas Macian; Bruno Pereira; Romain Valabrègue; Stéphane Lehericy; Louis Boyer; Claude Dubray; Betty Jean
Journal:  Drug Des Devel Ther       Date:  2015-07-23       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.